Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1427-1434

  Lee, Sang Hak ^a,c   Nam, Jae Kok ^a   Park, Jong Kok ^a,d   Lee, Joo Ho ^a,e   Min, Do Sik ^b   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Pusan National University   (South Korea)

^c Boryung Co Ltd   (South Korea)

^d NORTHWESTERN UNIVERSITY   (United States)

^e SunMoon University   (South Korea)

Author keywords

5 FU; Biomarker; Colorectal adenocarcinoma; Multicellular spheroid; Resistance

Indexed keywords

COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEIC ACID BINDING PROTEIN; PROTEIN PSF2; SELENIUM BINDING PROTEIN; SELENIUM BINDING PROTEIN 1; TIRAPAZAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; COLLAPSIN RESPONSE MEDIATOR PROTEIN-2; GINS2 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; NERVE PROTEIN; NONHISTONE PROTEIN; SELENBP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ARTICLE; CANCER CELL LINE; CANCER INHIBITION; COLORECTAL CANCER CELL LINE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MONOLAYER CULTURE; MULTICELLULAR SPHEROID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; APOPTOSIS; COLORECTAL TUMOR; DRUG EFFECTS; MASS SPECTROMETRY; METABOLISM; PROTEOMICS; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE TISSUE PROTEINS; PROTEOMICS; SELENIUM-BINDING PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84923068530     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3337     Document Type: Article

References (38)

1. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
2. Jorfi S and Inal JM: The role of microvesicles in cancer progression and drug resistance. Biochem Soc Trans 41: 293-298, 2013.
3. Nyga A, Cheema U and Loizidou M: 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal 5: 239-248, 2011.
4. Fridman WH, Dieu-Nosjean MC, Pages F, Cremer I, Damotte D, Sautes-Fridman C and Galon J: The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron 6: 117-122, 2013.
5. Fennema E, Rivron N, Rouwkema J, van Blitterswijk C and de Boer J: Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol 31: 108-115, 2013.
6. McMillin DW, Negri JM and Mitsiades CS: The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12: 217-228, 2013.
7. Morin PJ: Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 6: 169-172, 2003.
8. Wartenberg M, Gronczynska S, Bekhite MM, Saric T, Niedermeier W, Hescheler J and Sauer H: Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113: 229-240, 2005. (Pubitemid 39628313)
9. Yamada KM and Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610, 2007. (Pubitemid 47268064)
10. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, Panda AK and Labhasetwar V: 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm 5: 849-862, 2008.
11. Chitcholtan K, Sykes PH and Evans JJ: The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med 10: 38, 2012.
12. Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA and Lawrenson K: A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 93: 528-542, 2013.
13. Longati P, Jia X, Eimer J, Wagman A, Witt MR, Rehnmark S, Verbeke C, Toftgard R, Lohr M and Heuchel RL: 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer 13: 95, 2013.
14. Yeon SE, No da Y, Lee SH, Nam SW, Oh IH, Lee J and Kuh HJ: Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model. PLoS One 8: e73345, 2013.
15. Hehlgans S, Eke I, Storch K, Haase M, Baretton GB and Cordes N: Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol 92: 362-370, 2009.
16. Nirmalanandhan VS, Duren A, Hendricks P, Vielhauer G and Sittampalam GS: Activity of anticancer agents in a three-dimensional cell culture model. Assay Drug Dev Technol 8: 581-590, 2010.
17. Godugu C, Patel AR, Desai U, Andey T, Sams A and Singh M: AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 8: e53708, 2013.
18. Lombardi L, Gebbia V, Silvestris N, Testa A, Colucci G and Maiello E: Adjuvant therapy in colon cancer. Oncology 77: 50-56, 2009.
19. Neuman HB, Park J and Weiser MR: Randomized clinical trials in colon cancer. Surg Oncol Clin N Am 19: 183-204, 2010.
20. Kinoshita M, Kodera Y, Hibi K, Nakayama G, Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M and Nakao A: Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy. Anticancer Res 27: 851-856, 2007. (Pubitemid 46586990)
21. Zhang N, Yin Y, Xu SJ and Chen WS: 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13: 1551-1569, 2008.
22. Reddy SB and Williamson SK: Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18: 77-87, 2009.
23. LaRue KE, Khalil M and Freyer JP: Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors. Cancer Res 64: 1621-1631, 2004. (Pubitemid 38428682)
24. Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ and McDonnell TJ: The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 14: 336-347, 2009.
25. Nakamura T, Kato Y, Fuji H, Horiuchi T, Chiba Y and Tanaka K: E-cadherin-dependent intercellular adhesion enhances chemoresistance. Int J Mol Med 12: 693-700, 2003.
26. Tomasini R, Mak TW and Melino G: The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 18: 244-252, 2008.
27. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (Review). Int J Oncol 40: 639-644, 2012.
28. Lee EC, Lee YS, Park NH, So KS, Chun YJ and Kim MY: Ceramide induces apoptosis and growth arrest of human glioblastoma cells by inhibiting akt signaling pathways. Biomol Therap 19: 21-26, 2011.
29. Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 71: 829-842, 2013.
30. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
31. Lee CS, Kim KL, Jang JH, Choi YS, Suh PG and Ryu SH: The roles of phospholipase D in EGFR signaling. Biochim Biophys Acta 1791: 862-868, 2009.
32. Kang DW, Choi KY and Min do S: Phospholipase D meets Wnt signaling: a new target for cancer therapy. Cancer Res 71: 293-297, 2011.
33. Oliemuller E, Pelaez R, Garasa S, Pajares MJ, Agorreta J, Pio R, Montuenga LM, Teijeira A, Llanos S and Rouzaut A: Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC. Int J Cancer 132: 1986-1995, 2013.
34. Barkley LR, Song IY, Zou Y and Vaziri C: Reduced expression of GINS complex members induces hallmarks of pre-malignancy in primary untransformed human cells. Cell Cycle 8: 1577-1588, 2009.
35. Obama K, Ura K, Satoh S, Nakamura Y and Furukawa Y: Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma. Oncol Rep 14: 701-706, 2005.
36. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, Kim C, Song SY, Kim HJ, Lee C, et al : Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6: 3466-3476, 2006. (Pubitemid 43886162)
37. Zhang S, Li F, Younes M, Liu H, Chen C and Yao Q: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium. PLoS One 8: e63702, 2013.
38. Li T, Yang W, Li M, Byun DS, Tong C, Nasser S, Zhuang M, Arango D, Mariadason JM and Augenlicht LH: Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52: 1289-1299, 2008.